News Headlines Article

New heart drugs come in more expensive than expected

Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too much.

Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems.

But their positioning in the marketplace was always likely to be contentious since they offer more effective alternatives to very cheap, off-patent drugs.